Last reviewed · How we verify
BRV-PV Lot B + DPT-HepB-Hib + OPV
BRV-PV Lot B + DPT-HepB-Hib + OPV is a Combination vaccine Biologic drug developed by Serum Institute of India Pvt. Ltd.. It is currently in Phase 3 development for Prevention of rotavirus gastroenteritis in infants, Prevention of diphtheria, pertussis, and tetanus, Prevention of hepatitis B infection. Also known as: Live Attenuated human-bovine reassortant pentavalent rotavirus vaccine.
This is a combination vaccine that provides immunization against rotavirus (BRV-PV), diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, and poliomyelitis through inactivated and live attenuated viral/bacterial antigens.
This is a combination vaccine that provides immunization against rotavirus (BRV-PV), diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, and poliomyelitis through inactivated and live attenuated viral/bacterial antigens. Used for Prevention of rotavirus gastroenteritis in infants, Prevention of diphtheria, pertussis, and tetanus, Prevention of hepatitis B infection.
At a glance
| Generic name | BRV-PV Lot B + DPT-HepB-Hib + OPV |
|---|---|
| Also known as | Live Attenuated human-bovine reassortant pentavalent rotavirus vaccine |
| Sponsor | Serum Institute of India Pvt. Ltd. |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
BRV-PV (Rotavirus vaccine) stimulates mucosal and systemic immunity against rotavirus through live attenuated virus. The DPT-HepB-Hib component provides immunity against diphtheria and tetanus toxoids, acellular pertussis antigens, hepatitis B surface antigen, and Haemophilus influenzae type b conjugate. OPV (Oral Polio Vaccine) uses live attenuated poliovirus strains to induce intestinal and systemic immunity against poliovirus types 1, 2, and 3.
Approved indications
- Prevention of rotavirus gastroenteritis in infants
- Prevention of diphtheria, pertussis, and tetanus
- Prevention of hepatitis B infection
- Prevention of Haemophilus influenzae type b infection
- Prevention of poliomyelitis
Common side effects
- Fever
- Local injection site reactions (pain, swelling, erythema)
- Irritability
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRV-PV Lot B + DPT-HepB-Hib + OPV CI brief — competitive landscape report
- BRV-PV Lot B + DPT-HepB-Hib + OPV updates RSS · CI watch RSS
- Serum Institute of India Pvt. Ltd. portfolio CI
Frequently asked questions about BRV-PV Lot B + DPT-HepB-Hib + OPV
What is BRV-PV Lot B + DPT-HepB-Hib + OPV?
How does BRV-PV Lot B + DPT-HepB-Hib + OPV work?
What is BRV-PV Lot B + DPT-HepB-Hib + OPV used for?
Who makes BRV-PV Lot B + DPT-HepB-Hib + OPV?
Is BRV-PV Lot B + DPT-HepB-Hib + OPV also known as anything else?
What drug class is BRV-PV Lot B + DPT-HepB-Hib + OPV in?
What development phase is BRV-PV Lot B + DPT-HepB-Hib + OPV in?
What are the side effects of BRV-PV Lot B + DPT-HepB-Hib + OPV?
Related
- Drug class: All Combination vaccine drugs
- Manufacturer: Serum Institute of India Pvt. Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease Prevention
- Indication: Drugs for Prevention of rotavirus gastroenteritis in infants
- Indication: Drugs for Prevention of diphtheria, pertussis, and tetanus
- Indication: Drugs for Prevention of hepatitis B infection
- Also known as: Live Attenuated human-bovine reassortant pentavalent rotavirus vaccine
- Compare: BRV-PV Lot B + DPT-HepB-Hib + OPV vs similar drugs
- Pricing: BRV-PV Lot B + DPT-HepB-Hib + OPV cost, discount & access